Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02350816 · ClinicalTrials.gov registry record · Phase 2
An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.
A Phase 2 study, sponsored by Shire.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT02350816 is a Phase 2 study that was terminated before completion, run by Shire. The registered enrollment target is 17 participants.
The verdict
NCT02350816, a Phase 2 study, was terminated before completion, sponsored by Shire.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This extension study will allow participants to continue receiving treatment with HGT-1410 and to initiate treatment in patients who received no-treatment in Study HGT-SAN-093, and will evaluate the long-term safety and efficacy of the study drug.
Interventions
- DRUG HGT-1410
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2015-04-08 |
| Est. Completion | 2019-04-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02350816
The ClinicalTrials.gov registry entry for NCT02350816 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HGT-1410 is the first listed.
NCT02350816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02350816 about?
NCT02350816 is a clinical study titled "An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.". This extension study will allow participants to continue receiving treatment with HGT-1410 and to initiate treatment in patients who received no-treatment in Study HGT-SAN-093, and will evaluate the long-term safety and efficacy of the study drug.
What is the current status of trial NCT02350816?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2015-04-08. Estimated completion is 2019-04-12.
What interventions are being tested in trial NCT02350816?
The interventions under investigation include: HGT-1410 (DRUG).
Who is sponsoring clinical trial NCT02350816?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.